Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Trials

MRD trials

The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.

Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.

  • GI · PancreaticRecruitingPhase 2NCT07835893

    Lenvatinib Plus Chemotherapy for pNET Liver Metastases

    Peking Union Medical College Hospital · 1 locations · Updated 2026-09-23

  • GI · PancreaticRecruitingPhase 2NCT07096362

    Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

    University of Miami · 1 locations · Updated 2026-09-21

  • GI · PancreaticRecruitingPhase 2NCT05518903

    Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma

    Mayo Clinic · 1 locations · Updated 2026-08-10

  • GI · PancreaticRecruitingPhase 2NCT05929885

    Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

    National Cancer Centre, Singapore · 1 locations · Updated 2026-06-23

  • GI · Pancreatic, ColorectalRecruitingPhase 1 / Phase 2NCT07353645

    KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer

    The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 locations · Updated 2026-04-15

  • GI · Biliary, PancreaticRecruitingPhase 1 / Phase 2NCT06730009

    Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients

    Medigen Biotechnology Corporation · 1 locations · Updated 2025-12-17

  • GI · Pancreatic, Gastroesophageal, ColorectalRecruitingPhase 2NCT06333314

    Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

    UNICANCER · 22 locations · Updated 2025-12-02

  • GI · PancreaticNot yet recruitingPhase 2NCT05562297

    Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

    Shanghai Zhongshan Hospital · 1 locations · Updated 2025-01-22

  • GI · PancreaticRecruitingNot reportedObservationalNCT05052671

    ctDNA Assay in Patients With Resectable Pancreatic Cancer

    University of Oklahoma · 2 locations · Updated 2026-10-27

  • GI · PancreaticRecruitingNot reportedObservationalNCT07845617

    Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma

    AdventHealth · 1 locations · Updated 2026-09-29

  • GI · PancreaticRecruitingNot applicableNCT06574620

    Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

    British Columbia Cancer Agency · 1 locations · Updated 2026-09-16

  • GI · Liver / HCC, Biliary, PancreaticRecruitingNot applicableNCT05497531

    Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers

    University of California, Irvine · 1 locations · Updated 2026-08-31

  • GI · PancreaticNot yet recruitingNot reportedObservationalNCT07597252

    ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study)

    Chang Gung Memorial Hospital · 1 locations · Updated 2026-08-03

  • GI · Pancreatic, GastroesophagealRecruitingNot applicableNCT07660627

    Determining Minimal Residual Disease Using ctDNA Deep Sequencing

    Masaryk Memorial Cancer Institute · 1 locations · Updated 2026-06-24

  • GI · PancreaticRecruitingNot reportedObservationalNCT04616131

    Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

    Northwestern University · 3 locations · Updated 2026-06-18

  • GI · Pancreatic, ColorectalNot yet recruitingNot reportedObservationalNCT07605702

    The Canopy Cancer Collective Clinical Registry Protocol

    Canopy Cancer Collective, LLC · 10 locations · Updated 2026-05-26

  • GI · Pancreatic, Gastroesophageal, ColorectalNot yet recruitingNot reportedObservationalNCT07574957

    Prediction of Peritoneal Dissemination of Digestive Tumors Through the Study of Circulating Tumor DNA

    Assistance Publique - Hôpitaux de Paris · Locations not reported · Updated 2026-05-08

  • GI · PancreaticRecruitingNot reportedObservationalNCT05630989

    A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

    Mandana Kamgar, MD · 1 locations · Updated 2026-05-05

  • GI · PancreaticRecruitingNot applicableNCT05788744

    Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer

    Copenhagen University Hospital at Herlev · 5 locations · Updated 2026-03-27

  • GI · PancreaticRecruitingNot applicableNCT06353646

    XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

    Wu Wenming · 1 locations · Updated 2026-02-13

  • GI · PancreaticNot yet recruitingNot applicableNCT07396090

    Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Locations not reported · Updated 2026-02-09

  • GI · Biliary, Pancreatic, ColorectalRecruitingNot reportedObservationalNCT06202131

    Use of Ctdna in Patients With Gastrointestinal Tract Tumors

    Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 locations · Updated 2025-09-02

  • GI · PancreaticRecruitingNot reportedObservationalNCT07080021

    A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer

    Ruijin Hospital · 2 locations · Updated 2025-07-29

  • GI · PancreaticRecruitingNot applicableNCT06966440

    Adjuvant Pancreatic Therapy Guided by MRD

    Ruijin Hospital · 1 locations · Updated 2025-07-15

  • GI · PancreaticRecruitingNot reportedObservationalNCT06287749

    French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

    University Hospital, Montpellier · 1 locations · Updated 2025-07-10

  • GI · PancreaticRecruitingNot reportedObservationalNCT07054879

    CtDNA-guided Maintenance Therapy in Pancreatic Cancer

    The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 locations · Updated 2025-07-08

  • GI · PancreaticRecruitingNot reportedObservationalNCT07045571

    MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer

    Yingbin Liu, MD, PhD, FACS · 1 locations · Updated 2025-07-01

  • GI · PancreaticNot yet recruitingNot reportedObservationalNCT07034703

    Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial

    University Hospital, Rouen · 1 locations · Updated 2025-06-24

  • GI · PancreaticNot yet recruitingNot reportedObservationalNCT06941987

    Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer

    Shanghai Zhongshan Hospital · 1 locations · Updated 2025-04-24

  • GI · PancreaticRecruitingNot applicableNCT05298722

    Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)

    University Hospital, Ghent · 8 locations · Updated 2025-04-02

  • GI · PancreaticRecruitingNot reportedObservationalNCT05737953

    Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

    Zhaoshen Li · 1 locations · Updated 2025-02-11

  • GI · Liver / HCC, Biliary, PancreaticRecruitingNot reportedObservationalNCT06139042

    Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers

    Second Affiliated Hospital, Zhejiang University, School of Medicine · 1 locations · Updated 2025-02-10

  • GI · PancreaticNot yet recruitingNot reportedObservationalNCT06807112

    The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma

    Charles University, Czech Republic · 1 locations · Updated 2025-02-04

  • GI · PancreaticRecruitingNot reportedObservationalNCT06043921

    Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel

    Invitae Corporation · 1 locations · Updated 2023-09-21

  • GI · PancreaticRecruitingNot reportedObservationalNCT05556603

    AssesSment of Early-deteCtion basEd oN liquiD Biopsy in PANCEATIC Cancer (ASCEND-PANCREATIC)

    Ruijin Hospital · 3 locations · Updated 2023-05-06

Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.